Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Baker BROS. Advisors LP

Posted by Geri Gentry on Jun 18th, 2026

Baker BROS. Advisors LP cut its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 7.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,432,529 shares of the company’s stock after selling 123,580 shares during the quarter. Structure Therapeutics accounts for 0.6% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 26th biggest holding. Baker BROS. Advisors LP owned approximately 2.36% of Structure Therapeutics worth $99,632,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC raised its holdings in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares during the last quarter. HighTower Advisors LLC increased its position in Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after buying an additional 320 shares in the last quarter. State of Wyoming increased its position in Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after buying an additional 403 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Structure Therapeutics by 9.4% during the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after buying an additional 413 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after buying an additional 444 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Trading Up 4.9%

GPCR stock opened at $45.00 on Thursday. The stock has a 50-day moving average price of $43.09 and a two-hundred day moving average price of $57.53. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90. The company has a market cap of $3.20 billion, a PE ratio of -51.72 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on GPCR. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Citizens Jmp dropped their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Canaccord Genuity Group began coverage on Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Wolfe Research began coverage on Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Finally, BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

View Our Latest Stock Report on Structure Therapeutics

Structure Therapeutics Company Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.